Compare Figs Inc (FIGS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

FIGS stock trades at $18.63, up 4.9% today, showing strong momentum with three consecutive quarterly earnings beats. The company demonstrates robust fundamentals with 68.9% gross margins and accelerating revenue growth from $556M in 2024 to projected $710M in 2026. Technical indicators show bullish momentum with the stock trading near resistance at $19, though RSI levels suggest potential overbought conditions. Recent news highlights international expansion success with 67% Q2 international sales growth and raised 2026 guidance.

The outlook remains positive with analyst consensus pointing to 26% upside potential to $18 target, though the premium valuation (P/E 54.6) requires continued execution. Key risks include rich valuation multiples and competitive pressures in healthcare apparel. The combination of strong earnings momentum, international growth, and bullish technicals supports further upside if the company maintains its growth trajectory.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.